Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alketa Hamzaj

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Lung Cancer (Amsterdam, Netherlands)|October 24, 2006
Development of new first-line therapeutic options for non-small-cell lung cancerLucio Crinò, Jennifer Foglietta, Alketa Hamzaj
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 26, 2007
Lung cancerLucio Crinò, Jennifer Foglietta, Alketa Hamzaj
Expert Review of Anticancer Therapy|October 30, 2014
Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal viewSergio Bracarda, Michele Sisani, Francesca Marrocolo, et al.
Critical Reviews in Oncology/Hematology|December 7, 2013
GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancerSergio Bracarda, Michele Sisani, Francesca Marrocolo, et al.
Seminars in Oncology|May 13, 2015
Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignanciesSergio Bracarda, Amelia Altavilla, Alketa Hamzaj, et al.
Tumori|February 8, 2014
Sunitinib therapy in metastatic papillary thyroid cancerStefania Gori, Jennifer Foglietta, Marta Rossi, et al.
Future Oncology (London, England)|October 6, 2015
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluationSergio Bracarda, Claudia Caserta, Luca Galli, et al.
The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.
Plos One|July 7, 2018
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in ItalyMaria Giuseppa Vitale, Sarah Scagliarini, Luca Galli, et al.
European Urology|October 10, 2022
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 TrialFrancesca Vignani, Rosa Tambaro, Ugo De Giorgi, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Lung Cancer (Amsterdam, Netherlands)|October 24, 2006
Development of new first-line therapeutic options for non-small-cell lung cancerLucio Crinò, Jennifer Foglietta, Alketa Hamzaj
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 26, 2007
Lung cancerLucio Crinò, Jennifer Foglietta, Alketa Hamzaj
Expert Review of Anticancer Therapy|October 30, 2014
Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal viewSergio Bracarda, Michele Sisani, Francesca Marrocolo, et al.
Critical Reviews in Oncology/Hematology|December 7, 2013
GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancerSergio Bracarda, Michele Sisani, Francesca Marrocolo, et al.
Seminars in Oncology|May 13, 2015
Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignanciesSergio Bracarda, Amelia Altavilla, Alketa Hamzaj, et al.
Tumori|February 8, 2014
Sunitinib therapy in metastatic papillary thyroid cancerStefania Gori, Jennifer Foglietta, Marta Rossi, et al.
Future Oncology (London, England)|October 6, 2015
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluationSergio Bracarda, Claudia Caserta, Luca Galli, et al.
The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.
Plos One|July 7, 2018
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in ItalyMaria Giuseppa Vitale, Sarah Scagliarini, Luca Galli, et al.
European Urology|October 10, 2022
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 TrialFrancesca Vignani, Rosa Tambaro, Ugo De Giorgi, et al.
Pageof 2